CagriSema obesity drug: what the phase 3 data shows Novo Nordisk Submits CagriSema for FDA Approval for Obesity Treatment Dr. Jibran Khan R. Ph., CRCP., PhD posted on the topic LinkedIn What is cagrisema and how does it work for weight loss? Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet 1 CagriSema 2.4 mg 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or CagriSema's second phase 3 trial demonstrates 15.7% weight loss over 68 weeks. Michael Weintraub, MD